# Centaur

Sara E. Dempster

May 10, 2017 OHDSI Population level estimation WG

### Package 'Centaur'

April 5, 2017

Type Package

Title Centaur Propensity Score Balancing Workflow and Toolkit

Version 1.0.0

Date 2017-04-06

Author Sara Dempster Stephen Kottmann Alex Bayeh

Maintainer Alex Bayeh <alex.bayeh.centaur@gmail.com>

Description Performs propensity score based population balancing. This package is a toolkit to calculate propensity scores, balancea population dataset via either weighting or matching, and perform a variety of diagnostics to assess the scientific validity of the approach. The authors acknowledge the following team from AstraZeneca Pharmaceuticals, Robert Lo-Casale, Michael Goodman, Ramin Arani, Yiduo Zhang, and Sudeep Karve for contributing to the requirements with their expertise in epidemiology, safety informatics, health economics and biostatics and for reviewing the final product. The authors also acknowledge Jonathan Herz and Pramod Kumar for help with testing early versions of the package.

**License** Apache License 2.0

LazyData no

RoxygenNote 6.0.1


Imports AUC broom data table dolvr ff. gtools Hmisc MASS

### Background

- started as a component of an internal project at AZ for overall platform development to standardize and scale up observational data analysis
- team wanted a propensity score/cohort method workflow in R to validate against existing SAS code sets
- team wanted recommended workflows and parameter settings, but also flexible options for advanced users
- team wanted to draw on commonly used R packages i.e Twang, MatchIT, but have all integrated into one framework and workflow.
- main original use case = quick feasibility analysis on patient balance (exclude outcome analysis)
- package including outcome analysis was used for internal validation of CVD-REAL results

# Centaur

Workflow diagram



# Whitepaper coming soon




Figure 2 - "Phase Diagram" of available methods




Figure 3 – Computational time for PS calculation using Twang





Figure 4 - Computational time for PS calculation using GLM



| Trial | Number<br>of<br>Trees | Depth | Shrinkag<br>e | Bag<br>Fractio<br>n | Estiman<br>d | Time<br>to Run | Avg. %<br>Reduction<br>in Std.<br>Diff. of<br>Means |
|-------|-----------------------|-------|---------------|---------------------|--------------|----------------|---|
| 1     | 10000                 | 3     | 0.01          | 1                   | ATT          | 508 s          | 82.11439  |
| 2     | 5000                  | 3     | 0.01          | 1                   | ATT          | 469 s          | 81.98465  |
| 3     | 2000                  | 3     | 0.01          | 1                   | ATT          | 378 s          | 81.36216  |
| 4     | 1000                  | 3     | 0.01          | 1                   | ATT          | 347 s          | 77.14936  |
| 5     | 10000                 | 3     | 0.005         | 1                   | ATT          | 499 s          | 81.22527  |
| 6     | 10000                 | 3     | 0.05          | 1                   | ATT          | 514 s          | 81.22527  |
| 7     | 10000                 | 3     | 0.1           | 1                   | ATT          | 508 s          | 82.62994  |
| 8     | 10000                 | 2     | 0.01          | 1                   | ATT          | 456 s          | 88.67967  |
| 11    | 10000                 | 3     | 0.01          | 1                   | ATE          | 538 s          | 82.05354  |
| 12    | 5000                  | 2     | 0.01          | 1                   | ATT          | 405 s          | 92.02401  |




Figure 5 – Performance comparison of GLM and twang

# Vignette coming soon

### **Load Data**


A simple dataset has been included in the drive.ps package to support this vignette. The full T2DM cohort has been downsampled to include 40k samples for each of the drug classes (with the exception of AGI). The data is included as an internal resource, and the details of the data can be viewed with:

```
ps.getDataAvailability()
             DRUGCLASS freq
## 1
                   AGI 810
## 2
             Biguanide 40000
           Combinations 40000
## 3
                  DPP4 40000
## 4
## 5
                Insulin 40000
           No T2DM Drug 40000
## 6
                 Other 40000
          Sulfonylureas 40000
## 9 Thiazolidinediones 40000
```

A utility method has been included in the package to create new datasets for comparing any two of these treatment groups. For this vignette, create a dataset comparing Biguanides to a No Drug control group:

```
myData <- ps.createDataset("Biguanide", 10000, control.name = "No T2DM Drug", control.number
= 20000)
```

### **Distribution of Propensity Scores**




### **Calculate Propensity Scores**


Propensity scores are calculated via the ps.score method. The primary inputs to this method are the dataset, the list of covariates to include in the calculation, and the propensity score method. The two methods available are 'glm' and 'twang' (twang is, by default, only available for datasets with less than 30k samples).

```
mvData <- ps.score(mvData, T2DM.covariates, ps.method = "alm")
## Call: glm(formula = formula, family = binomial(), data = data, control = list(maxit =
## Coefficients:
## (Intercept)
                   DXFLAG
                              A1FLAG
                                                     0.007213
## -1.247274
                 1.811913
                             0.618708
                                         0.660038
                                         LIPIDCM
                                                     OBESECM
         AGE
                     CCI
                               HTNCM
## -0.026565
                -0.097182
                           -0.079160
                                        -0.239265
                                                    -0.142157
## bin.15.20. bin.20.25.
                           bin.25.30. bin.30.35.
                                                   bin.35.40
## -1.198418
               -1.322439
                           -0.713089
                                       -0.152973
## bin.40.45.
               bin.45.50.
                           bin.50.55.
                                       bin.55.60.
                            0.435822
                                        0.480809
   0.108488
                 0.279788
              bin.10.20.
                           bin.20.30. bin.30.40. bin.40.50.
   bin.65.70.
                      NA
## bin.50.60.
              bin.60.70.
           NA
## Degrees of Freedom: 29999 Total (i.e. Null); 29980 Residual
## Residual Deviance: 37430
```

The data frame returned by ps.score includes the original T2DM cohort data frame, but has added a new variable ps\_values.

### Covariate Std. Diff. Reduction





## variable selection

### Variable Selection for Propensity Score Models •

M. Alan Brookhart ™, Sebastian Schneeweiss, Kenneth J. Rothman, Robert J. Glynn, Jerry Avorn, Til Stürmer

Am J Epidemiol (2006) 163 (12): 1149-1156. **DOI:** https://doi.org/10.1093/aje/kwj149

Published: 19 April 2006 Article history ▼

### **Abstract**

Despite the growing popularity of propensity score (PS) methods in epidemiology, relatively little has been written in the epidemiologic literature about the problem of variable selection for PS models. The authors present the results of two simulation studies designed to help epidemiologists gain insight into the variable selection problem in a PS analysis. The simulation studies illustrate how the choice of variables that are included in a PS model can affect the bias, variance, and mean squared error of an estimated exposure effect. The results suggest that variables that are unrelated to the exposure but related to the outcome should always be included in a PS model. The inclusion of these variables will decrease the variance of an estimated exposure effect without increasing bias. In contrast, including variables that are related to the exposure but not to the outcome will increase the variance of the estimated exposure effect without decreasing bias. In very small studies, the inclusion of variables that are strongly related to the exposure but only weakly related to the outcome can be detrimental to an estimate in a mean squared error sense. The addition of these variables removes only a small amount of bias but can increase the variance of the estimated exposure effect. These simulation studies and other analytical results suggest that standard model-building tools designed to create good predictive models of the exposure will not always lead to optimal PS models, particularly in small studies.